Part of the GenScript Biotech Global Forum, this Conversation will Explore Innovations to Shape the Future Success of Cell Therapy
London, UK – November 20, 2024 – Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announced today that Jason C. Foster, Chief Executive Officer, will participate in a panel session titled “Technology Innovation and Breakthroughs in Cell Therapy” at the Jefferies London Healthcare Conference. The conference is taking place in London from November 19 to 21, 2024.
Panel Details:
Date: Wednesday, November 20, 2024
Time: 2:25 p.m. – 3:05 p.m. GMT
Location: 116 Pall Mall, London SW1Y 5ED, UK
Moderator:
Stephen Hansen, Director of Biopharma Intelligence, BioCentury
Panelists:
- Pascal Touchon, Ph.D., Chairman of the Board, Atara Biotherapeutics
- Biao Zheng, Ph.D., CEO, BRL Medicine Inc.
- Ying Huang, Ph.D., CEO, Legend Biotech
- Jason Foster, CEO and Executive Director, Ori Biotech
- Reagan Jarvis, Ph.D., CEO and Co-Founder, Anocca AB
For more information, visit the forum website.
About Ori Biotech
Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori’s next-generation manufacturing platform, automates better biology, accelerates product development, and enables therapy developers to scale their products’ clinical and commercial impact. IRO® seamlessly transitions from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughout, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics.
For news and updates, visit Ori Biotech News & Insights.